upgrad xph downstream effect
pharmaceut etf rang exposur
second largest pharmaceut compani us third largest
world therefor differ etf weight methodolog market cap weight equal
weight drive wide rang exposur stock across industri
etf exposur across etf rang high low less
outlook stock integr assess rel valu across
pharmaceut etf pharma etf within coverag univers most-
to-least exposur ihe pjp pph xph
downgrad updat sum part valuat
buy neutral lower price object base
updat sum part valuat follow expect dilut upjohn unit
spin-off gerberri ultim believ decis spin-off upjohn unit make
strateg sens given like meaning drag growth allow
focu innov pharma unit howev stock work
remainco would need trade forward multipl ep view
unlik given current portfolio mix
upgrad spdr pharma etf xph attract
follow gerberri downgrad upgrad spdr
pharmaceut etf xph attract less attract owe
part view fund rel underweight exposur due
fund equal weight methodolog longer neg april ratio
exposur stock rate buy vs under-perform bofaml research
higher peer averag today ratio
peer averag see improv fundament factor
around underli exposur xph technic effici factor hold fund back
reach threshold attract rate
pph top pick pharma etf effici technic
vaneck vector pharmaceut etf pph remain etf top pick
industri exposur mainli owe fund screen best across two
three segment analysi technic effici rel low expens
ratio best track secondari market liquid rel tight
trade spread drive view pph effici etf option
pharmaceut categori strongest price momentum highest sharp ratio
drive view pph attract technic perspect
exposur pph stock bofaml analyst rate buy vs peer averag
categori outlook pharma etf remain neutral view
maintain categori outlook etf coverag
neutral view owe industri maintain rank within bofaml
 momentum valu framework account price momentum earn
revis valuat right line averag industri
bofa merril lynch seek busi issuer cover research report
result investor awar firm may conflict interest could
affect object report investor consid report singl
factor make invest decis
refer import disclosur page analyst certif page price object
basis/risk page
chart pharma etf exposur pfizer
correl
price object po base part sotp analysi includ
remainco stake upjohn-myl
remainco assum compani trade multipl ep
remainco vs current averag us/eu pharma group
risk sale downsid us sale continu declin and/or competit
take meaning market share ibranc could lead downsid estim
po inabl grow busi line forecast hold opex
spend flat level throughout forecast period transact
perceiv valu destruct
mari ann bartel jason gerberri herebi certifi view us
express research report accur reflect respect person
view subject secur issuer also certifi part
respect compens directli indirectli relat specif
recommend view express research report
bofa merril lynch current act financi advisor abu dhabi nation oil
compani adnoc connect propos midstream pipelin infrastructur
partnership kkr announc februari
adnoc addit enter follow-on pipelin infrastructur invest
agreement abu dhabi retir pension benefit fund adrpbf
announc april
us major specialti pharmaceut coverag cluster
compani
refer opinion na longer valid nr rate
invest opinion system contain end report head exchange-trad fund opinion dark grey shade indic secur restrict opinion suspend medium
grey shade indic secur review opinion withdrawn grey shade indic secur cover chart current june later date indic
refer opinion na longer valid nr rate
invest opinion system contain end report head exchange-trad fund opinion dark grey shade indic secur restrict opinion suspend medium
grey shade indic secur review opinion withdrawn grey shade indic secur cover chart current june later date indic
invest opinion system contain end report head fundament equiti opinion dark grey shade indic secur restrict opinion suspend medium grey
shade indic secur review opinion withdrawn grey shade indic secur cover chart current june later date indic
refer opinion na longer valid nr rate
invest opinion system contain end report head exchange-trad fund opinion dark grey shade indic secur restrict opinion suspend medium
grey shade indic secur review opinion withdrawn grey shade indic secur cover chart current june later date indic
refer opinion na longer valid nr rate
rate dispers may vari time time bofa merril lynch research believ better reflect invest prospect stock coverag cluster
incom rate indic potenti cash dividend same/high dividend consid secur same/low dividend consid secur pay
cash dividend coverag cluster compris stock cover singl analyst two analyst share common industri sector region classif stock
coverag cluster includ recent bofa merril lynch report referenc stock
exchange-trad fund etf invest opinion opinion reflect outlook rate categori rate outlook rate reflect analyst assess etf
attract rel etf within categori includ sector region asset class themat other three outlook rate etf attract cover
peer categori next month etf similarli attract cover peer categori next month etf less attract
cover peer categori next month categori rate indic analyst view etf categori incorpor publish view bofaml
global research depart analyst fv favor view nv neutral view uf unfavor view
price chart secur referenc research report avail http //pricechart baml com call mail
bofa one affili act market maker equiti secur recommend report invesco pharma etf ishar pharma etf spdr pharma etf vect pharma
invest opinion system contain end report head exchange-trad fund opinion dark grey shade indic secur restrict opinion suspend medium
grey shade indic secur review opinion withdrawn grey shade indic secur cover chart current june later date indic
equiti invest rate distribut servic group jun
equiti invest rate distribut health group jun
equiti invest rate distribut global group jun
issuer invest bank client bofa merril lynch one affili within past month purpos invest rate distribut coverag univers includ stock
stock rate neutral includ hold stock rate under-perform includ sell
exchange-trad fund invest rate distribut global group jun
exchange-trad fund etf etf provid invest bank client bofa merril lynch one affili within past month purpos invest rate distribut
coverag univers includ etf etf rate includ buy etf rate includ hold etf rate includ sell
price fluctuat medium high invest rate reflect analyst assess stock absolut total return potenti ii
attract invest rel stock within coverag cluster defin three invest rate buy stock expect total
return least attract stock coverag cluster neutral stock expect remain flat increas valu less attract
buy rate stock under-perform stock least attract stock coverag cluster analyst assign invest rate consid among thing
month total return expect stock firm guidelin rate dispers shown tabl current price object stock
referenc better understand total return expect given time price object reflect analyst view potenti price appreci depreci
fundament equiti opinion opinion includ volatil risk rate invest rate incom rate volatil risk rate indic potenti
total return expect within period date initi rate
rate dispers guidelin coverag cluster
bofa affili manag public offer secur issuer within last month inc state street corp
issuer within last month invest bank client bofa and/or one affili inc state street corp
bofa affili receiv compens issuer non-invest bank servic product within past month inc state street corp
issuer within last month non-secur busi client bofa and/or one affili inc state street corp vaneck
bofa affili receiv compens invest bank servic issuer within past month inc state street corp
bofa affili expect receiv intend seek compens invest bank servic issuer affili issuer within next three month
bofa togeth affili benefici own one percent common stock issuer report issu day month reflect
ownership posit last day previou month report issu day month reflect ownership posit end second month preced date
report
bofa togeth affili benefici own one percent share fund report issu day month reflect ownership
posit last day previou month report issu day month reflect ownership posit end second month preced date report
bofa one affili will sell buy client common equiti issuer princip basi invesco pharma etf ishar pharma etf spdr pharma etf
issuer within last month secur busi client non-invest bank bofa and/or one affili inc
bofa merril lynch research personnel includ analyst respons report receiv compens base upon among factor overal profit america
corpor includ profit deriv invest bank analyst respons report may also receiv compens base upon among factor overal
profit bank sale trade busi relat class secur financi instrument analyst respons
bofa and/or affili particip creation redempt etf author particip etf invesco pharma etf ishar pharma etf spdr pharma etf
